| Name | Title | Contact Details |
|---|
SpineWorks Medical is a Huntington Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blue Stream Laboratories is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nu Image Medical specializes in Weight Loss, Hormone Replacement, Sexual Enhancement and General Wellness. Our futuristic methods offer a new and updated approach to achieving optimum health and wellness not only through local brick-and-mortar establishments, but also online virtually through our telemedicine platform. Nu Image Medical has been proving patient services nationally since 2004, establishing itself as not on a leader in Regenerative Medicine, but also in the Telehealth industry. Nu Image Medical sets the standard for patients looking to receive quality expert medical care without boundaries.
Cenduit is the leading IRT systems specialist in the world, with rapid study startup software, clinical supply chain intelligence, clinical operations know-how and customer-centric CORE teams making sure your study starts quickly and runs smoothly. Other IRT-driven services include patient randomization and trial supply management (RTSM), integration, patient engagement and materials forecasting. We have over 500 experts worldwide in the US, UK, Switzerland, India, Japan and China, with clinical trial experience in more than 100 countries, interacting with more than 600,000 patients at more than 32,000 sites. Let Cenduit`s experts ensure that your study needs are met on time and within budget.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.